Serum Cotinine (Nicotine metabolite)

Hormone/ Element

Report in 48Hrs

At Home

No Fasting Required

Details

Nicotine exposure marker.

₹1,776₹2,537

30% OFF

Serum Cotinine (Nicotine Metabolite) - Comprehensive Medical Test Guide

Why is it done?
- Test Description: Serum cotinine is a primary metabolite of nicotine that is measured to detect and quantify tobacco smoke exposure, including active smoking, secondhand smoke (passive smoking), and nicotine replacement therapy use.
- Primary Indications: Assessment of smoking status in patients who deny tobacco use; verification of smoking cessation; evaluation of secondhand smoke exposure; monitoring compliance with smoking restriction policies; documentation of nicotine exposure in clinical or occupational settings; assessment of prenatal tobacco exposure; research and epidemiological studies on smoking prevalence.
- Typical Timing/Circumstances: During routine health screening; prior to surgical procedures to assess perioperative risk; at the initial visit to establish baseline smoking status; during pulmonary or cardiovascular workup; in occupational health settings; when evaluating discrepancies between reported and suspected smoking status; during pregnancy to assess fetal exposure; in substance abuse or rehabilitation programs.
Normal Range
- Reference Ranges: Non-smokers: <0.05 ng/mL (or <0.3 nmol/L) – typically undetectable or minimal baseline levels Passive smokers/secondhand smoke exposure: 0.05-0.5 ng/mL Light smokers: 0.5-5 ng/mL Active smokers: >5 ng/mL, typically ranging from 5-1000 ng/mL depending on frequency and intensity Heavy smokers: >300 ng/mL, often exceeding 500 ng/mL Detection limit varies by laboratory; some sensitive assays can detect levels as low as 0.01 ng/mL
- Units of Measurement: ng/mL (nanograms per milliliter) – most common in clinical practice nmol/L (nanomoles per liter) – used in some international laboratories Conversion factor: 1 ng/mL ≈ 6.16 nmol/L
- Interpretation of Results: Negative/Non-detectable (<0.05 ng/mL): No current tobacco smoke exposure; non-smoker status Positive (>0.05 ng/mL): Tobacco smoke exposure detected; indicates active or passive smoking Borderline (0.05-0.5 ng/mL): May indicate minimal exposure, recent secondhand smoke, or recent cessation Elevated (>5 ng/mL): Consistent with active smoking status High (>100 ng/mL): Indicates heavy smoking or intense tobacco use
- What Normal vs Abnormal Means: Normal (undetectable): Absence of recent nicotine exposure from any source; supports non-smoker status and minimal environmental tobacco smoke exposure Abnormal (detectable): Presence of nicotine metabolite indicates active smoking, passive smoke exposure, or nicotine replacement therapy use; requires clinical correlation and patient counseling
Interpretation
- Detailed Result Interpretation: Undetectable to Very Low (<0.05 ng/mL): Confirms non-smoker status; no exposure to nicotine from tobacco or therapeutic sources; most reliable period for this result is within 7-10 days of last exposure Low Positive (0.05-0.5 ng/mL): Suggests environmental/passive smoke exposure or very light smoking; may indicate recent cessation with residual cotinine; cotinine half-life of 15-20 hours explains detection several days after last use Moderate (0.5-5 ng/mL): Consistent with light-to-moderate active smoking or substantial secondhand smoke exposure; distinguishes active from passive smokers High (5-100 ng/mL): Indicates active smoking status; positive correlation with smoking frequency and intensity; useful for verification of smoking cessation programs Very High (>100 ng/mL): Consistent with heavy smoking, chain smoking, or intensive nicotine use; associated with greater health risks and higher difficulty in smoking cessation
- Factors Affecting Results: Time since last tobacco exposure: Cotinine has a half-life of 15-20 hours; detectable for 2-3 weeks after cessation Nicotine replacement therapy (NRT): Patches, gum, lozenges, and inhalers will produce measurable cotinine levels despite smoking abstinence Environmental/passive smoke exposure: Prolonged exposure to secondhand smoke can elevate levels into detectable range Dietary factors: Certain foods (eggplants, tomatoes) contain trace nicotine but contribute negligibly to serum levels Pregnancy: Pregnancy status does not significantly affect cotinine metabolism, though placental transfer occurs Genetic variations: Cytochrome P450 (CYP2A6) enzyme polymorphisms affect nicotine metabolism rates Medications: Certain drugs may inhibit CYP2A6 and slow cotinine metabolism Individual metabolism: Variations in metabolic rate affect how quickly cotinine is eliminated Collection timing: Results vary depending on time of day and since last cigarette
- Clinical Significance of Result Patterns: Declining levels over time: Indicates successful smoking cessation; useful for monitoring abstinence programs Plateaued high levels: Suggests ongoing active smoking despite patient denial or heavy continued use Sudden increase from baseline: May indicate relapse in smoking cessation efforts; warrants clinical intervention and counseling Persistent low-positive levels: Consistent with NRT use or minimal environmental exposure; distinguishes true passive smokers from active smokers Discordant history and results: Patient denying smoking but positive results suggests either unreliable patient history or recent exposure; important for perioperative risk stratification
Associated Organs
- Primary Organ Systems Involved: Respiratory System: Primary route of tobacco smoke exposure; chronic obstructive pulmonary disease (COPD), lung cancer, asthma exacerbation Cardiovascular System: Nicotine increases heart rate and blood pressure; associated with coronary artery disease, myocardial infarction, stroke, and arrhythmias Liver: Primary site of cotinine metabolism via hepatic enzymes; elevated levels indicate recent nicotine exposure Kidneys: Cotinine excretion occurs through renal filtration; renal function affects clearance rates Brain/Nervous System: Nicotine is a neurotropic agent; affects neurotransmitter function and addiction pathways Placenta (in pregnancy): Cotinine crosses placental barrier; intrauterine exposure affects fetal development
- Medical Conditions Associated with Abnormal Results: Pulmonary Diseases: Chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, lung cancer, asthma with smoking exposure Cardiovascular Diseases: Hypertension, coronary artery disease, peripheral vascular disease, cerebrovascular disease, increased thrombotic risk Neoplastic Diseases: Lung cancer, laryngeal cancer, oral cancer, esophageal cancer, pancreatic cancer, bladder cancer Pregnancy-Related Complications: Intrauterine growth restriction, preterm delivery, low birth weight, increased miscarriage risk Infectious Diseases: Increased susceptibility to respiratory infections; impaired immune response Metabolic Disorders: Increased risk of type 2 diabetes mellitus in active smokers; impaired glucose metabolism Psychiatric Conditions: Nicotine dependence, anxiety disorders, depression with self-medication through smoking
- Diseases Diagnosed or Monitored by Elevated Cotinine: Nicotine dependence: Confirmed through elevated serum levels Active tobacco use: Establishes objective smoking status independent of patient reporting Secondhand smoke-related illnesses: Documentable exposure in non-smoking individuals Perioperative complications: Predicts higher surgical risk and delayed wound healing Fetal exposure-related complications: Associated with adverse perinatal outcomes Relapsed smoking: Detected through rising cotinine levels in cessation programs
- Potential Complications Associated with Abnormal Results: Acute cardiovascular events: Myocardial infarction, stroke, sudden cardiac death Acute respiratory decompensation: Severe asthma attacks, acute exacerbation of COPD Surgical complications: Increased bleeding, impaired wound healing, increased infection risk, increased thromboembolic events Cancer progression: Advanced malignancy development with continued exposure Fetal complications: Preterm labor, spontaneous abortion, fetal demise, developmental abnormalities Withdrawal complications: During cessation attempts; management requires medical support Drug interactions: Smoking induces CYP1A2 enzymes affecting metabolism of various medications
Follow-up Tests
- Additional Tests Based on Abnormal Results: Pulmonary Function Tests (PFTs): To assess lung capacity and function in smokers or those with respiratory complaints Chest X-ray or High-Resolution CT: To screen for smoking-related lung pathology or malignancy Electrocardiogram (ECG): To assess for smoking-related cardiac changes or arrhythmias Lipid Panel: To evaluate cardiovascular risk in active smokers Blood Glucose/Hemoglobin A1C: To screen for smoking-related metabolic dysfunction Carboxyhemoglobin (COHb): Alternative marker for acute tobacco smoke exposure Thiocyanate levels: Another tobacco smoke metabolite marker Urine cotinine: Confirmatory testing; longer detection window than serum Hair cotinine: Provides 3-month retrospective exposure assessment
- Further Investigations Based on Clinical Context: In perioperative setting: Preoperative cardiac workup if high-risk; consider delayed elective surgery for smoking cessation In pregnancy: Fetal ultrasound for growth assessment; non-stress testing; obstetric consultation for high-risk pregnancy management In pulmonary symptoms: Chest imaging and spirometry; pulmonology referral if abnormalities detected In cardiovascular symptoms: Stress testing, echocardiography, cardiac catheterization as indicated In cancer screening: Age-appropriate and risk-stratified lung cancer screening (LDCT); screening for other smoking-associated malignancies In cessation programs: Behavioral assessment; psychology or psychiatry referral; addiction medicine consultation
- Monitoring Frequency for Ongoing Conditions: Smoking Cessation Programs: Baseline cotinine at enrollment; repeat testing at 2-4 week intervals to monitor abstinence; final assessment at program completion Active Smokers with Chronic Disease: Annual or biennial cotinine measurement to assess continued smoking status and health risk Pregnant Smokers: Cotinine testing at each trimester to monitor ongoing exposure and counsel on cessation Perioperative Patients: Single preoperative cotinine test to establish baseline smoking status and surgical risk Research Studies: Baseline, periodic (monthly to annual), and final assessments depending on study design Occupational Health Monitoring: Annual or event-based testing in smoke-free workplace compliance settings
- Related Tests Providing Complementary Information: Urine Cotinine: Gold standard for long-term exposure assessment; detectable for 2-3 weeks; better for population screening Hair Cotinine: Measures cumulative exposure over 3-6 months; stable marker not affected by recent changes Carboxyhemoglobin (COHb): Measures acute carbon monoxide exposure from smoking; reflects recent (within 24 hours) exposure Thiocyanate: Another smoking metabolite; less specific than cotinine but useful for confirmation Nicotine: Direct measure of nicotine; rapid elimination makes cotinine more useful clinically Lung Function Tests: Objective assessment of smoking-induced pulmonary changes Smoking Questionnaires (Fagerström Test): Subjective assessment of nicotine dependence severity; complements objective cotinine results
Fasting Required?
- Fasting Requirement: NO – Fasting is NOT required for serum cotinine testing. This test can be performed at any time of day without regard to food or fluid intake.
- Medications to Avoid: No medications need to be withheld for serum cotinine testing However, patients using nicotine replacement therapy (patches, gum, lozenges, inhalers, nasal spray) should continue normal use, as this is important for accurate interpretation Patients should inform the phlebotomist if they are currently using any form of nicotine replacement therapy Certain medications that inhibit CYP2A6 enzyme (phenethyl isothiocyanates, minocycline) may theoretically affect metabolism, but this does not require medication avoidance—only clinical awareness
- Other Patient Preparation Requirements: Standard venipuncture preparation: Patient should sit comfortably for 5 minutes prior to blood draw No special positioning required; can be seated or supine Arm should be relaxed and supported during blood collection Inform phlebotomist of current smoking status or nicotine use Timing considerations: For most accurate results, avoid collecting blood immediately after smoking a cigarette; ideally wait 30-60 minutes post-cigarette for more stable readings Specimen collection: Standard 5-10 mL blood draw into plain (gold-top serum separator) tube No special container required; standard SST (serum separator tube) is acceptable Specimen stability: Stable at room temperature for up to 24 hours, or refrigerated at 2-8°C for several days Patient identification and labeling: Ensure proper labeling with patient name, medical record number, date, and time of collection Documentation: Clinical indication for testing should be noted in patient chart (smoking status assessment, cessation monitoring, perioperative evaluation, etc.) Verbal confirmation: Verify patient identity immediately before blood draw to ensure correct specimen labeling

How our test process works!